{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:41:39Z","timestamp":1790757699071,"version":"4.1.0"},"reference-count":53,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T00:00:00Z","timestamp":1466553600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Chemotherapy-induced peripheral neuropathy is a common side effect of selected chemotherapeutic agents. Previous work has suggested that patients often under report the symptoms of chemotherapy-induced peripheral neuropathy and physicians fail to recognize the presence of such symptoms in a timely fashion. The precise pathophysiology that underlies chemotherapy-induced peripheral neuropathy, in both the acute and the chronic phase, remains complex and appears to be medication specific. Recent work has begun to demonstrate and further clarify potential pathophysiological processes that predispose and, ultimately, lead to the development of chemotherapy-induced peripheral neuropathy. There is increasing evidence that the pathway to neuropathy varies with each agent. With a clearer understanding of how these agents affect the peripheral nervous system, more targeted treatments can be developed in order to optimize treatment and prevent long-term side effects.<\/ns4:p>","DOI":"10.12688\/f1000research.8053.1","type":"journal-article","created":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T16:59:46Z","timestamp":1466614786000},"page":"1466","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":94,"title":["Chemotherapy-induced peripheral neuropathy: an update on the current understanding"],"prefix":"10.12688","volume":"5","author":[{"given":"James","family":"Addington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8282-764X","authenticated-orcid":false,"given":"Miriam","family":"Freimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2016,6,22]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"304-11","DOI":"10.1002\/ana.410350310","article-title":"Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.","volume":"35","author":"V Chaudhry","year":"1994","journal-title":"Ann Neurol."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"1991-6","DOI":"10.1007\/s00520-010-1043-2","article-title":"Burden of chemotherapy-induced neuropathy--a cross-sectional study.","volume":"19","author":"A Kautio","year":"2011","journal-title":"Support Care Cancer."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"173-83","DOI":"10.1097\/NCC.0b013e3181c989a3","article-title":"The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums.","volume":"33","author":"E Smith","year":"2010","journal-title":"Cancer Nurs."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"15-49","DOI":"10.1053\/j.seminoncol.2005.12.010","article-title":"Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.","volume":"33","author":"F Hausheer","year":"2006","journal-title":"Semin Oncol."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"3355-64","DOI":"10.1007\/s00520-012-1492-x","article-title":"Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.","volume":"20","author":"K Shimozuma","year":"2012","journal-title":"Support Care Cancer."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"2461-70","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.","volume":"155","author":"M Seretny","year":"2014","journal-title":"Pain."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"623-9","DOI":"10.1111\/ene.12353","article-title":"Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies.","volume":"21","author":"T Kr\u00f8ig\u00e5rd","year":"2014","journal-title":"Eur J Neurol."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"e00354","DOI":"10.1002\/brb3.354","article-title":"Assessment of chemotherapy-induced peripheral neuropathy using the LDIFLARE technique: a novel technique to detect neural small fiber dysfunction.","volume":"5","author":"S Sharma","year":"2015","journal-title":"Brain Behav."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"188-92","DOI":"10.1111\/j.1468-1331.2012.03852.x","article-title":"Ultrasound assessment of oxaliplatin-induced neuropathy and correlations with neurophysiologic findings.","volume":"20","author":"C Briani","year":"2013","journal-title":"Eur J Neurol."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"220-33","DOI":"10.1006\/nbdi.2001.0468","article-title":"Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling.","volume":"9","author":"E McDonald","year":"2002","journal-title":"Neurobiol Dis."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"443-7","DOI":"10.1023\/A:1008231925889","article-title":"Carboplatin toxic effects on the peripheral nervous system of the rat.","volume":"9","author":"G Cavaletti","year":"1998","journal-title":"Ann Oncol."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"128-35","DOI":"10.1345\/aph.1E319","article-title":"Oxaliplatin-associated neuropathy: a review.","volume":"39","author":"R Cersosimo","year":"2005","journal-title":"Ann Pharmacother."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"2205-11","DOI":"10.1200\/JCO.2006.08.6652","article-title":"Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.","volume":"25","author":"S Land","year":"2007","journal-title":"J Clin Oncol."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"13-6","DOI":"10.1159\/000094376","article-title":"Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up.","volume":"56","author":"A Pietrangeli","year":"2006","journal-title":"Eur Neurol."},{"key":"ref-15","doi-asserted-by":"crossref","first-page":"2293-7","DOI":"10.1152\/jn.2001.85.5.2293","article-title":"A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels.","volume":"85","author":"F Grolleau","year":"2001","journal-title":"J Neurophysiol."},{"key":"ref-16","first-page":"15","article-title":"Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice.","volume":"6","author":"L Ta","year":"2010","journal-title":"Mol Pain."},{"key":"ref-17","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/180428","article-title":"Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve.","volume":"2014","author":"M Quartu","year":"2014","journal-title":"Biomed Res Int."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"847-56","DOI":"10.1007\/s00280-009-1017-6","article-title":"Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity.","volume":"64","author":"J Liu","year":"2009","journal-title":"Cancer Chemother Pharmacol."},{"key":"ref-19","first-page":"483-6","article-title":"Neuronal drug transporters in platinum drugs-induced peripheral neurotoxicity.","volume":"34","author":"G Cavaletti","year":"2014","journal-title":"Anticancer Res."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"563-8","DOI":"10.1016\/j.bcp.2010.11.016","article-title":"Organic cation transporter OCT\/SLC22A and H+\/organic cation antiporter MATE\/SLC47A are key molecules for nephrotoxicity of platinum agents.","volume":"81","author":"A Yonezawa","year":"2011","journal-title":"Biochem Pharmacol."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"253-65","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs.","volume":"4","author":"M Jordan","year":"2004","journal-title":"Nat Rev Cancer."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"726-9","DOI":"10.1001\/archneur.1994.00540190110024","article-title":"Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings.","volume":"51","author":"Z Sahenk","year":"1994","journal-title":"Arch Neurol."},{"key":"ref-23","first-page":"5349-53","article-title":"Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells'.","volume":"60","author":"N Andr\u00e9","year":"2000","journal-title":"Cancer Res."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"154-61","DOI":"10.1016\/j.expneurol.2011.08.016","article-title":"Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy.","volume":"232","author":"H Zheng","year":"2011","journal-title":"Exp Neurol."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"1046-57","DOI":"10.1523\/JNEUROSCI.4497-07.2008","article-title":"Interaction of transient receptor potential vanilloid 4, integrin, and SRC tyrosine kinase in mechanical hyperalgesia.","volume":"28","author":"N Alessandri-Haber","year":"2008","journal-title":"J Neurosci."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"E2189-98","DOI":"10.1073\/pnas.1525096113","article-title":"Paclitaxel-induced epithelial damage and ectopic MMP-13 expression promotes neurotoxicity in zebrafish.","volume":"113","author":"T Lisse","year":"2016","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2016.02.011","article-title":"Dorsal root ganglion infiltration by macrophages contributes to paclitaxel chemotherapy-induced peripheral neuropathy.","author":"H Zhang","year":"2016","journal-title":"J Pain."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"560-8","DOI":"10.1097\/j.pain.0000000000000404","article-title":"Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel.","volume":"157","author":"L Ventzel","year":"2016","journal-title":"Pain."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"23-7","DOI":"10.1007\/BF01050259","article-title":"Long-term effects of vincristine on the peripheral nervous system.","volume":"15","author":"T Postma","year":"1993","journal-title":"J Neurooncol."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"6806-14","DOI":"10.1021\/bi953037i","article-title":"Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.","volume":"35","author":"S Lobert","year":"1996","journal-title":"Biochemistry."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"e89583","DOI":"10.1371\/journal.pone.0089583","article-title":"Spinal changes of a newly isolated neuropeptide endomorphin-2 concomitant with vincristine-induced allodynia.","volume":"9","author":"Y Yang","year":"2014","journal-title":"PLoS One."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"R811-8","DOI":"10.1152\/ajpregu.00543.2007","article-title":"Cyclosporine increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system.","volume":"294","author":"C Wang","year":"2008","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"880-92","DOI":"10.1007\/s12031-013-0095-4","article-title":"Structural and molecular alterations of primary afferent fibres in the spinal dorsal horn in vincristine-induced neuropathy in rat.","volume":"51","author":"K Thibault","year":"2013","journal-title":"J Mol Neurosci."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"262-70","DOI":"10.1016\/j.pain.2007.06.001","article-title":"Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine.","volume":"135","author":"W Xiao","year":"2008","journal-title":"Pain."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"877-8","DOI":"10.1212\/01.WNL.0000049462.03800.B1","article-title":"Thalidomide-induced neuropathy: a ganglionopathy?","volume":"60","author":"F Giannini","year":"2003","journal-title":"Neurology."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"4507-14","DOI":"10.1200\/JCO.2006.05.6689","article-title":"Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.","volume":"24","author":"L Mileshkin","year":"2006","journal-title":"J Clin Oncol."},{"key":"ref-37","doi-asserted-by":"crossref","first-page":"366-7","DOI":"10.5694\/j.1326-5377.2004.tb05980.x","article-title":"Thalidomide-induced bradycardia and its management.","volume":"180","author":"J Coutsouvelis","year":"2004","journal-title":"Med J Aust."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"2123-32","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.","volume":"357","author":"M Dimopoulos","year":"2007","journal-title":"N Engl J Med."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"859-88","DOI":"10.2165\/00003495-200969070-00006","article-title":"Bortezomib: a review of its use in patients with multiple myeloma.","volume":"69","author":"M Curran","year":"2009","journal-title":"Drugs."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"151-67","DOI":"10.2147\/JPR.S32122","article-title":"CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats.","volume":"5","author":"C Meregalli","year":"2012","journal-title":"J Pain Res."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"317-25","DOI":"10.1016\/j.expneurol.2006.11.010","article-title":"Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.","volume":"204","author":"G Cavaletti","year":"2007","journal-title":"Exp Neurol."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"940-9","DOI":"10.4161\/cc.7.7.5625","article-title":"Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.","volume":"7","author":"M Poruchynsky","year":"2008","journal-title":"Cell Cycle."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"3828-36","DOI":"10.1158\/0008-5472.CAN-04-3684","article-title":"Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341\/bortezomib) cytotoxicity in myeloma cell lines.","volume":"65","author":"T Landowski","year":"2005","journal-title":"Cancer Res."},{"key":"ref-44","first-page":"913-24","article-title":"Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.","volume":"1","author":"M Shahshahan","year":"2011","journal-title":"Am J Cancer Res."},{"key":"ref-45","first-page":"5453-9","article-title":"Antibody against tumor necrosis factor-\u03b1 reduces bortezomib-induced allodynia in a rat model.","volume":"33","author":"A Chiorazzi","year":"2013","journal-title":"Anticancer Res."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"1175-9","DOI":"10.1007\/s00520-015-2898-z","article-title":"Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: a single-center retrospective study.","volume":"24","author":"T Kus","year":"2016","journal-title":"Support Care Cancer."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"815-23","DOI":"10.1001\/jama.2015.0894","article-title":"Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.","volume":"313","author":"B Diouf","year":"2015","journal-title":"JAMA."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"1223-31","DOI":"10.1007\/s00520-013-2075-1","article-title":"Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.","volume":"22","author":"Y Guo","year":"2014","journal-title":"Support Care Cancer."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"997-1005","DOI":"10.1200\/JCO.2013.52.0536","article-title":"Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB\/Alliance).","volume":"32","author":"C Loprinzi","year":"2014","journal-title":"J Clin Oncol."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"1890-7","DOI":"10.1002\/cncr.28654","article-title":"North Central Cancer Treatment Group\/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel\/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study.","volume":"120","author":"A Leal","year":"2014","journal-title":"Cancer."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"1807-14","DOI":"10.1007\/s00520-014-2158-7","article-title":"A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors.","volume":"22","author":"J Gewandter","year":"2014","journal-title":"Support Care Cancer."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"1359-67","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.","volume":"309","author":"E Smith","year":"2013","journal-title":"JAMA."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"866-71","DOI":"10.1007\/s10147-015-0810-y","article-title":"Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial.","volume":"20","author":"Y Hirayama","year":"2015","journal-title":"Int J Clin Oncol."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/5-1466\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/5-1466\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/5-1466\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T14:51:59Z","timestamp":1600786319000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/5-1466\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,22]]},"references-count":53,"URL":"https:\/\/doi.org\/10.12688\/f1000research.8053.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.8664.r14527","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.8664.r14528","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.8664.r14528","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.8664.r14527","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,22]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/5-1466\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.8664.r14528, Amanda Peltier, Department of Neurology, Vanderbilt University School of Medicine, Nashville, TN, USA, 22 Jun 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-1466\/v1#referee-response-14528","order":0,"name":"referee-response-14528","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.8664.r14527, Jonathan D. Glass, Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA, 22 Jun 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-1466\/v1#referee-response-14527","order":1,"name":"referee-response-14527","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}